MedTrace Logo

A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity

NCT07690826 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2026-07-08

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes. Approximately 252 participants will be enrolled. The primary endpoint is percent change in body weight from baseline at Week 32 versus placebo.

Conditions

  • Overweight or Obesity

Interventions

DRUG

HRS-4729 Injection

HRS-4729 Injection; Dose 1

DRUG

HRS-4729 Injection

HRS-4729 Injection; Dose 2

DRUG

HRS-4729 Injection

HRS-4729 Injection; Dose 3

DRUG

HRS-4729 Injection;

HRS-4729 Injection; Dose 4

DRUG

HRS-4729 Injection;

HRS-4729 Injection; Dose 5

DRUG

HRS-4729 Injection;

HRS-4729 Injection; Dose 6

DRUG

HRS-4729 Injection Placebo

HRS-4729 Injection Placebo

Sponsors & Collaborators

  • Fujian Shengdi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2027-03-31
Completion
2027-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07690826 on ClinicalTrials.gov